Gilead Sciences is in advanced negotiations to acquire Ouro Medicines for up to $2 billion, a deal announced on March 23 2026. The transaction would involve a $1.5 billion upfront cash payment and an additional $500 million contingent on the achievement of specified clinical milestones, according to the Financial Times.
Ouro Medicines, founded in January 2025, raised $120 million in Series A funding led by Monograph Capital and GSK. The company focuses on immune‑reset therapeutics for chronic immune‑mediated diseases, with a lead asset, OM336, licensed from Keymed Biosciences. Its pipeline includes T‑cell engagers and B‑cell biology programs designed to induce durable remissions without ongoing immunosuppression.
The acquisition would broaden Gilead’s immunology and oncology reach, complementing existing programs from MiroBio and Forty Seven and aligning with the company’s strategy to expand beyond its core HIV and liver disease franchises. Gilead’s recent $7.8 billion purchase of Arcellx further underscores its aggressive growth in immunology and inflammation.
The deal is expected to add new therapeutic areas and accelerate development timelines for Ouro’s assets, providing Gilead with a diversified pipeline and positioning it to address unmet needs in autoimmune diseases. No immediate market reaction data are available, but the announcement represents a significant strategic move for Gilead.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.